about
PET Tracer 18F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models.Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN7-14 and Antagonist RM26.Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent.Genetics of lipid metabolism in prostate cancer.Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PET Tracers Beyond FDG in Prostate Cancer.
@en
PET Tracers Beyond FDG in Prostate Cancer.
@nl
type
label
PET Tracers Beyond FDG in Prostate Cancer.
@en
PET Tracers Beyond FDG in Prostate Cancer.
@nl
prefLabel
PET Tracers Beyond FDG in Prostate Cancer.
@en
PET Tracers Beyond FDG in Prostate Cancer.
@nl
P2860
P1476
PET Tracers Beyond FDG in Prostate Cancer
@en
P2093
Cristina Nanni
P2860
P304
P356
10.1053/J.SEMNUCLMED.2016.07.005
P577
2016-09-07T00:00:00Z